Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Address: 1Laboratory of Molecular Biology and Immunobiotechnology, Department of Biochemistry, Hellenic Pasteur Institute, 127 Vas. Sofias
Ave., 11521 Athens, Greece and 2Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Ave., 11522
Athens, Greece
Email: Alexios Dimitriadis - aldimitriadis@pasteur.gr; Chrysanthi Gontinou - xrisanthi78@yahoo.gr;
Constantin N Baxevanis - baxevanis@ciic.gr; Avgi Mamalaki* - amamalaki@pasteur.gr
* Corresponding author
Abstract
Background: Her2/neu is overexpressed in various human cancers of epithelial origin and is
associated with increased metastatic potential and poor prognosis. Several attempts have been
made using the extracellular domain of Her2/neu (ECD/Her2) as a prophylactic vaccine in mice
with no success in tumor prevention.
Methods: The extracellular domain of Her2/neu (ECD/Her2) was expressed in yeast P. pastoris, in
a soluble highly mannosylated form. The immune response of the immunization with this
recombinant ECD/Her2 was analyzed using immunoprecipitation and western blot analysis,
proliferation and cytotoxicity assays as well as specific tumor growth assays.
Results: Mannosylated ECD/Her2 elicited a humoral response with HER2/neu specific antibodies
in vaccinated mice, which were able to reduce the proliferation rate of cancer cells in vitro.
Moreover, it elicited a cellular response with Her2/neu-specific CTL capable of lysing tumor cells,
in vitro. When immunized Balb/c and HHD mice were challenged with Her2/neu-overexpressing
cells, tumor growth was inhibited.
Conclusion: Here we report on the efficacy of the extracellular domain of human Her2/neu
produced in yeast P. pastoris, which confers mannosylation of the protein, to act as a potent anti-
tumor vaccine against Her2/neu overexpressing tumors. Specific cellular and humoral responses
were observed as well as efficacy.
Page 1 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
The Her2/neu gene has a low expression in normal tis- Cell lines
sues. However, it is amplified and overexpressed in ~30% D2F2/E2, a mouse mammary tumor cell line stably trans-
of invasive breast carcinomas and it is associated with fected with the human Her2/neu molecule, was previ-
increased metastatic potential and poor prognosis. Over- ously described [17]. This cell line, as well as the parental
expression of the Her2/neu receptor is also observed in D2F2 cell line, was maintained in hi-glucose DMEM, sup-
various other human cancers, including lung, ovary, kid- plemented with 100 units/mL Penicillin, 100 μg/mL
ney, and bladder [3]. Several reports have shown that the Streptomycin, 10% FBS, 10% NCTC 109, 1% non-essen-
Her2/neu molecule is immunogenic, since it may gener- tial amino acids and 5% Sodium Bicarbonate.
ate antibodies and peptide-specific CTL response in some
patients [4]. Therefore Her2/neu is an attractive target for ALC.A2.1.hHer2, a murine lymphoma cell line stably
active immunotherapy. DNA- and peptide-based vaccines transfected with the HLA.A2.1 and the human Her2/neu
were able to break tolerance and generate tumor antigen- molecule [8] and the SK-BR-3 cell line were maintained in
specific immunity in animal models [5-8]. However, RPMI 1640, supplemented with 100 units/mL Penicillin,
when the extracellular domain of the Her2/neu protein, 100 μg/mL Streptomycin and 10% FBS.
produced in cell lines which confer normal mammalian
glycosylation, was used as a vaccine, it could not confer All cell lines were maintained at 37°C under a 5% CO2 -
protection against Her2/neu overexpressing tumors [9- 95% air atmosphere.
11]. An effective immune response was elicited only when
ECD/Her2 was fused to cytokines [12] or combined with Soluble expression of ECD/Her2 in yeast Pichia pastoris
antibodies fused to cytokines [11]. Given that antigen pre- The extracellular domain of human Her2/neu receptor
senting cells (APCs) do recognize and direct manno- (ECD/Her2, aminoacid residues 1 - 627) was previously
sylated antigens for degradation [13], it was recently enzymatically amplified by PCR and subcloned into the
shown that the use of fungal systems to mannosylate vac- expression vector pPICZaC (Invitrogen, Carlsbad, Califor-
cine candidates can enhance immunogenicity in the con- nia, USA) for soluble expression in yeast P. pastoris [18].
text of CD4+ [14] and CD8+ T cells [15]. The present study Protein production was induced with methanol while
utilizes the mannosylated extracellular domain of the cells were grown at 30°C for 72 h. The culture supernatant
human HER2/neu receptor (ECD/Her2) produced in yeast was passed through a 0.22 - μm membrane filter, concen-
P. pastoris to reduce tumor growth. ECD/Her2 elicited a trated using the Minitan Ultrafiltration System (Millipore,
humoral response in vaccinated mice with specific anti- Billerica, Massachusetts, USA) equipped with 30 kDa cut-
bodies against Her2/neu that were able to reduce the pro- off membrane and then dialyzed extensively against 20
liferation rate of cancer cells in vitro. It, also, elicited a mM sodium phosphate buffer pH 7.4, containing 0.5 M
cellular response with Her2/neu-specific CTL capable of NaCl and 10 mM Imidazole. The concentrated protein
lysing tumor cells in vitro. When Balb/c and HHD vacci- was purified over a Ni2+ affinity chromatography using
nated mice were challenged with Her2/neu overexpress- HisTrap FF column and a FPLC AKTA Purifier system
ing cells, tumor growth was inhibited. These results (Amersham Biosciences, Munich, Germany) under native
suggest that ECD/Her2 is a good candidate for a tumor conditions, according to the manufacturer's protocol. The
antigen vaccine as it prolongs tumor free survival and recombinant protein was filtrated and stored at -80°C.
overall survival of vaccinated mice.
In order to deglycosylate the produced molecule, approx-
Methods imately 3 μg of ECD/Her2 were denatured at 100°C for 10
Animals min in a buffer containing 0.5% SDS and 1% β-mercap-
Female BALB/c obtained from Harlan Laboratories (Indi- toethanol. 50 mM sodium phosphate and natural phos-
anapolis, IN, USA) and HHD mice (β2 m-/-, H-2Db-/- and phate (NP) to a final concentration of 1% were added,
expressing a HLA.A2.1 monochain composed of a chi- and the protein was incubated with 500 U N-glycosidase
meric heavy chain, α1 and α2 domains of HLA-A*0201 F (PNGase F, New England Biolabs, Ipswich, Massachu-
and the α3 intracellular domain of Db [16]) obtained setts, USA) for 1 h at 37°C, in a total reaction volume of
from Institut Pasteur (Paris, France), were used. 80 μl.
Page 2 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
ried out 21 and 42 days later. Mice weight was measured rabbit anti-Her2/neu (Santa Cruz Biotechnology, Santa
as an indicator of toxicity caused by vaccinations. Blood Cruz, California, USA), overnight at 4°C. Goat anti-rabbit
samples were taken by tail bleeding before each vaccina- IgG conjugated to horseradish peroxidase (DAKO Cyto-
tion, as well as 10, 21 and 42 days after the last vaccina- mation, Glostrup, Denmark) was the secondary antibody
tion. and bound antibodies were visualized by chemilumines-
cence using the ECL-Western Blot detection system
Tumor model (Amersham, Munich, Germany). Membranes were
10 days after the last immunization mice were challenged exposed to X-ray film (Amersham, Munich, Germany).
by s.c. injection into the left flank of 1 × 105 D2F2/E2 or
D2F2 tumor cells (BALB/c mice), or 3 × 105 SK-BR-3 in vitro proliferation assay
ALC.A2.1.hHer2 tumor cells (HHD mice). Tumor cells Single cell suspensions of 5 × 103 SK-BR-3 cells were left to
were suspended in sterile PBS. Animals were monitored adhere overnight at 96-well culture plates at 100 μL/well
twice per week for the development of palpable tumors. of RPMI-1640 containing 5% FBS. Pooled sera from each
Tumors were measured by calliper and the tumor volume group of vaccinated mice were depleted of complement
was calculated using the formula tumor volume = (length by incubation at 56°C for 30 minutes, diluted in serum-
× width2)/2. Mice were sacrificed with euthanasia when free culture medium to give a final working dilution of
the tumor volume grew up to 2000 mm3. 1:100 and added to SK-BR-3 cells, which were then incu-
bated for 3 days at 37°C. The number of living cells was
ELISA assay determined by CellTiter 96 Aqueous One Solution Cell
Sera from immunized mice were analyzed for anti-ECD/ Proliferation Assay (Promega, Madison, Wisconsin, USA).
Her2 reactivity in enzyme-linked immunosorbent assays
(ELISA). Ninety-six-well microtiter plates were coated Cytotoxicity assay
with 20 μg/mL ECD/Her2 for 16 hrs at 4°C. Non-specific ECD/Her2 or PBS immunized mice were used 10 days
binding sites were blocked with PBS/3% BSA for 1 h at after the last vaccination, to isolate CD8+ T cells from total
37°C. Plates were incubated with sera dilutions in PBS/ immune splenocytes by negative selection using the
1% BSA, in triplicates, overnight at 4°C. Anti-ECD/Her2 CD8a+ T Cell Isolation Kit (Miltenyi Biotec, Bergisch Glad-
antibodies were detected using goat anti-mouse IgG con- bach, Germany). Freshly isolated CD8+ T cells were used
jugated to horseradish peroxidase (DAKO Cytomation, for cytotoxicity assays using the CytoTox 96 Non-Radioac-
Glostrup, Denmark) in PBS/1% BSA, for 1 h at 37°C. tive Cytotoxicity Assay (Promega, Madison, Wisconsin,
Reactions were developed after the addition of TMB sub- USA). Briefly, 5000 D2F2 or D2F2/E2 cells were coated in
strate, and then stopped with the addition of 50 μL/well 1 each well of a 96-well v-bottom culture plate as target
M sulfuric acid. Absorbance was read on a microtiter plate cells. As effector cells, CD8+ T cells from immunized mice
reader (BioRad, Hercules, California, USA). were used at the indicated E:T ratios. Cytotoxicity is meas-
ured upon the lactate dehydrogenase (LDH) released
Immunoprecipitation and Western blot analysis upon cell lysis. The percentage of cytotoxicity is calculated
Pooled sera from groups of immunized mice were used to according to the formula % cytotoxicity = 100 × (experi-
immunoprecipitate human Her2/neu from SK-BR-3 cell mental value - effector spontaneous LDH release - target
membrane lysates. 1 μg Herceptin (Trastuzumab) was spontaneous LDH release)/(target maximum LDH release
used as a positive control, and PBS as negative control. - target spontaneous LDH release). Cytotoxicity values
200 μL beads Gammabind Sepharose (Amersham, were considered to indicate significant lytic activity of a
Munich, Germany) were pre-incubated with SK-BR-3 cell target when the differences between mean values for %
membrane lysate for 2 hours at room temperature, in lysis of target cells from ECD/Her2 vaccinated mice and
order to avoid any non-specific binding. 2 μL of sera were PBS vaccinated mice were >10% and statistically signifi-
incubated with 600 μg of cell membrane lysate overnight cant (p < 0.05).
at 4°C. 30 μL of Gammabind Sepharose were added and
the solution was gently rocked for 2 h at room tempera- Statistical analysis
ture. Sepharose pellets were washed twice with TSA solu- The statistical significance of differential findings between
tion (0.01 M Tris-HCl pH 8, 0.14 M NaCl, 0.025% NaN3) experimental groups was determined by student's t test.
containing 0.1% Triton-X and once with TSA alone. Findings were regarded as significant, if p values were <
0.05. Tumor sizes among the groups were compared with
Immunoprecipitates were separated on 8% SDS-PAGE Mann-Whitney U test using the SPSS (v.16.0) program.
gels and blotted onto PROTRAN nitrocellulose mem- Kaplan-Meier curves were plotted for tumor free analysis.
branes (WHATMAN, Dassel, Germany). The membranes All p values were two tailed and considered significant
were blocked with 5% non-fat milk in PBS, 0.1% Tween- when p < 0.05.
20. Her2/neu was detected by immunoblotting with C-18
Page 3 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
Vaccination with the mannosylated ECD/Her2 expressed In order to investigate whether these antibodies produced
in P. pastoris elicits a humoral response against Her2/neu in ECD/Her2- immunised mice were able to react with the
To determine whether the recombinant mannosylated native human Her2/neu, we performed immunoprecipi-
ECD/Her2 expressed in yeast P. pastoris could induce a tation assay. As shown in figure 3, the antibodies pro-
humoral immune response, groups of BALB/c mice were duced in ECD/Her2-immunized mice were specific
immunized with the recombinant protein or PBS emulsi- against the native Her2/neu receptor of SK-BR-3 cells.
fied in CFA s.c., followed by two boosts in IFA on days 21 These antibodies were not present in sera from PBS-
and 42. Immunized mice with the recombinant human immunised mice.
Page 4 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
Figure 2 with the mannosylated ECD/Her2 expressed in P. pastoris elicits a humoral response
Vaccination
Vaccination with the mannosylated ECD/Her2 expressed in P. pastoris elicits a humoral response. Anti-ECD/
Her2 antibodies in the sera of mice immunized with ECD/Her2 or PBS, as measured with enzyme-linked immunosorbent assay
(ELISA). Sera were collected at various times. Pooled sera from the two groups of mice were assayed at a 1:1000 dilution. Col-
umns and error bars represent the means and the range of values obtained from 3 independent experiments. ECD mice: ECD/
Her2 vaccinated mice. PBS mice: PBS vaccinated mice (control group).
liferation rate of SK-BR-3 by 13% (p < 0.05). In contrast, In vivo antitumor activity of the recombinant ECD/Her2 in
no cell growth arrest was noted with sera from PBS-vacci- HHD mice
nated mice, whereas Herceptin that was used as positive The in vivo antitumor activity of the recombinant ECD/
control antibody showed a strong inhibition effect (35%) Her2 was also evaluated in a second animal model.
at 6 nM. These data show that the antibodies contained in Groups of HHD mice were injected s.c. with ECD/Her2 (n
sera from ECD/Her2-immunized mice have significant = 4) or PBS (n = 4) on day 0, followed by two boosts on
anti-proliferative effects in SK-BR-3 cells. days 21 and 42. Specific antibodies against the ECD/Her2
and the native Her2/neu were developed in ECD/Her2
CD8+ T cells from immunized mice are able to lyse tumor vaccinated mice that were able to reduce the proliferation
target cells rate of SK-BR-3 cells (data not shown). 10 days after the
Having demonstrated that ECD/Her2 vaccination elicits last boost (day 52) mice were challenged s.c. into the left
antibodies capable of reducing the proliferation rate of flank with 3 × 105 ALC tumor cells stably transfected with
Her2-overexpressing tumor cells, we then sought to eval- Her2/neu and HLA.A2.1 (ALC.A2.1.hHer2). Tumors grew
uate Her2/neu-specific CTL responses induced in the progressively in all PBS immunized mice. Impressively,
same mice. Splenocytes were prepared 10 days after the however, ECD/Her2 immunization fully protected 3 out
last immunization, and CD8+ T cells were isolated using of 4 (75%) mice against tumor growth (figure 7).
CD8a+ T Cell Isolation Kit. As shown in figure 6, CD8+ T
cells isolated from PBS-immunized mice showed basal Discussion
lytic activity against D2F2/E2 cells, while CD8+ T cells iso- In the present study we showed that immunization with
lated from ECD/Her2-immunized mice exhibited signifi- the mannosylated extracellular domain of the human
cantly increased lytic activity (p < 0.01). Negligible levels Her2/neu receptor produced in yeast P. pastoris can induce
of cytotoxicity against wild type D2F2 cells were observed anti-Her2/neu antibodies capable of reducing the prolifer-
with CD8+ T cells isolated from ECD/Her2- or PBS-immu- ation rate of SK-BR-3 cells in vitro. In addition, manno-
nized mice (data not shown). sylated ECD/Her2 vaccination elicits specific CTL
responses against Her2/neu overexpressing tumor cells.
Both humoral and cellular responses delay and in some
Page 5 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
Page 6 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
Figure 4
Immunization with ECD/Her2 induces strong antitumor immunity in mice
Immunization with ECD/Her2 induces strong antitumor immunity in mice. Groups of 9 mice were injected as
described in Materials and Methods either with ECD/Her2 or with PBS on days 0, 21, and 42. 10 days after the last injection,
mice were inoculated s.c. with 105 D2F2/E2 cells. This is one representative experiment of 3 performed. A. Kaplan-Meier
curve was plotted for tumor free analysis. Unbroken line represents ECD/Her2 vaccinated mice and broken line PBS vacci-
nated mice (control group). B. Tumor growth in groups of vaccinated mice. The volume of individual tumors was calculated as
(length × width2)/2. Curves represent individual mice. Black square represents ECD/Her2 vaccinated mice and open circle PBS
vaccinated mice (control group). p < 0.01.
Figure
SK-BR-3
Influence5cells
of immunized sera on the in vitro proliferation of target+ Tcells
CD8
Figure 6cells from immunized mice are able to lyse tumor
Influence of immunized sera on the in vitro prolifera- CD8+ T cells from immunized mice are able to lyse
tion of SK-BR-3 cells. Diluted sera from ECD/Her2-immu- tumor target cells. In vitro CTL activity of CD8 T lym-
nized mice were able to reduce the proliferation rate by 13% phocytes isolated from spleens of BALB/c mice immunized
(p < 0.05). SK-BR-3 cells were incubated with complement with ECD/Her2 (black square) or PBS (open circle). CD8 T
inactivated pooled immune sera obtained from vaccinated cells from these mice were used as CTL effectors against
mice one day prior to cell inoculation. Immune sera were D2F2/E2 targets at the indicated E/T ratios and exhibited sig-
diluted 1:100. Columns and error bars represent the means nificantly increased lytic activity (p < 0,01). Points and error
and the range of values obtained from 3 independent experi- bars represent the means and the range of values obtained
ments. Positive control: Herceptin. from 3 independent experiments.
Page 7 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
Negative selection in the thymus is capable of deleting are the same with the HLA.A2.1-restricted ones binding
almost all of self-reactive T cells [25,26]. However, with different affinities to the mouse class I alleles, or rep-
because this process is not complete, several peripheral resent distinct ones, remains to be determined. Thus, the
tolerance mechanisms persist [26]. Because most known identification of the immunogenic epitopes on ECD/Her2
tumor antigens, including Her2/neu, come from self-pro- represents the major aim of our future studies. Once these
tein, these incompletely removed self-reactive T cells must have been identified, work will be needed to examine
be activated before being applied to tumor immuno- their immunogenicity in the human system.
therapy. Recently, several reports have shown that xeno-
genic vaccination could break self-tolerance and inhibit Conclusion
the progression of established tumor in syngeneic or Taken altogether, our results show that mannosylation of
transgenic mouse models [27-29]. In our study, xenogenic ECD/Her2 increases its capacity to act as an immunogenic
immunization with recombinant human ECD/Her2 molecule in vivo, being effective as a vaccine. This may
induced robust antitumor responses against murine have a broader applicability as a general concept for
tumor cell lines overexpressing human Her2/neu. Given increasing the potency of long-peptide or protein vac-
the high homology between human and murine Her2/ cines.
neu [30], we propose that our human ECD/Her2 vaccine
will also induce cross-reactive CTL against murine Her2/ Competing interests
neu, rejecting transplantable tumors expressing murine The authors declare that they have no competing interests.
Her2/neu, thus breaking tolerance against self-Her2/neu,
as also proposed in other tumor models based on xeno- Authors' contributions
vaccinations [8,31]. In addition, given that ECD/Her2 is a AM, AD and CNB designed the study. AD did the experi-
potential source of immunogenic determinants recog- ments and drafted the manuscript. CG was involved in
nized by CD4+ T helper cells [32], then it is obvious that cell cultures and purification of ECD/Her2. All authors
activation of the latter cell population will also lead to approved the final version of the manuscript.
generation of B cell clones producing anti-Her2/neu anti-
bodies, thus overcoming any tolerance mechanisms Acknowledgements
affecting the B cell compartment. This work was supported by grants from the PENED program of the GSRT
(contract No. 03ED113).
The data from the injections in BALB/c mice also suggest
We thank Dr Francois Lemonnier (Unite d'Immunite Cellulaire Antivirale,
that in addition to the HLA.A2.1, H-2Kd and Dd-restricted
Institut Pasteur, Paris, France) for kindly providing the HHD mouse strain
CTL epitopes on ECD/Her2 should exist. Whether these and Dr. S. Avrameas for valuable suggestions.
Page 8 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:386 http://www.biomedcentral.com/1471-2407/9/386
Page 9 of 9
(page number not for citation purposes)